checkAd

DGAP-News CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021

Nachrichtenquelle: EQS Group AG
09.04.2021, 13:20  |  139   |   |   

DGAP-News: CureVac / Key word(s): Miscellaneous
CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021

09.04.2021 / 13:20
The issuer is solely responsible for the content of this announcement.


CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021

TÜBINGEN, Germany/ BOSTON, USA - April 9, 2021 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results and business updates for the fourth quarter and Full-Year of 2020 on Thursday, April 15, 2021. The company will host a conference call and webcast on the same day at 4:00 p.m. CET / 10:00 a.m. EST.

Conference call and webcast details

Dial-in numbers to participate in the conference call:
U.S. Toll-Free: +1 877-407-0989
International: +1 201-389-0921
Germany: 0800 182 0040

The live webcast link can be accessed via the Investor Relations section of the CureVac homepage at https://www.curevac.com/en/newsroom/events/
Corresponding presentation slides will be posted shortly before the start of the webcast. A replay will be made available at this website after the event.

About CureVac
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 600 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

Seite 1 von 3
CureVac Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de




Diskussion: CureVac ist endlich an der Börse
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-News CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 DGAP-News: CureVac / Key word(s): Miscellaneous CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 09.04.2021 / 13:20 The issuer is solely responsible for the content of this …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel